newsfilter
← Latest News
Business Wire·

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

  • AN2 Therapeutics announced that CEO Eric Easom will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET.
  • Management members will be available for 1x1 meetings during the event.
  • The webcast is accessible via the Investors section of www.an2therapeutics.com with an archived replay available for at least 30 days.
  • AN2 Therapeutics is a clinical stage biopharmaceutical company focused on small-molecule therapeutics derived from its boron chemistry platform.
  • The company's pipeline includes three Phase 2 studies expected to be active in 2026, two preclinical candidates, & advanced research programs targeting oncology, bone disorders, & infectious diseases.
  • Development efforts span hematologic diseases, infectious diseases, & oncology to address critical unmet needs.